NAS:NKTR (USA) Also trade in: Germany UK

Nektar Therapeutics Inc

$ 31.57 -0.45 (-1.41%)
Volume: 253,032 Avg Vol (1m): 1,616,099
Market Cap $: 5.56 Bil Enterprise Value $: 4.42 Bil
P/E (TTM): 9.07 P/B: 3.40
Earnings Power Value -23.47
Net Current Asset Value 5.51
Tangible Book 8.96
Projected FCF 9.01
Median P/S Value 62.19
Graham Number 26.63
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 5.61
Cash-To-Debt ranked lower than
58.81% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NKTR: 5.61
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.72, Med: 1.57, Max: 389.59
Current: 5.61
0.72
389.59
Equity-to-Asset 0.75
Equity-to-Asset ranked higher than
68.15% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NKTR: 0.75
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.21, Med: 0.36, Max: 0.92
Current: 0.75
-0.21
0.92
Debt-to-Equity 0.15
Debt-to-Equity ranked higher than
67.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
NKTR: 0.15
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -909.95, Med: 1.16, Max: 73.27
Current: 0.15
-909.95
73.27
Debt-to-EBITDA 0.35
Debt-to-EBITDA ranked higher than
82.65% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
NKTR: 0.35
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -48.71, Med: -2.82, Max: 0.35
Current: 0.35
-48.71
0.35
Interest Coverage 14.96
Interest Coverage ranked lower than
80.60% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
NKTR: 14.96
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 14.96, Med: 16.08, Max: 16.08
Current: 14.96
14.96
16.08
Piotroski F-Score 8
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.67
DISTRESS
GREY
SAFE
Beneish M-Score 0.06
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 161.24%
WACC 22.69%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 55.26
Operating Margin ranked higher than
98.11% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NKTR: 55.26
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -173.39, Med: -41.21, Max: 57.65
Current: 55.26
-173.39
57.65
Net Margin % 55.65
Net Margin ranked higher than
96.97% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NKTR: 55.65
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -211.67, Med: -63.99, Max: 57.09
Current: 55.65
-211.67
57.09
ROE % 46.64
ROE ranked higher than
99.70% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NKTR: 46.64
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -379.68, Med: -101.4, Max: 75.47
Current: 46.64
-379.68
75.47
ROA % 35.12
ROA ranked higher than
99.54% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NKTR: 35.12
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -34.75, Med: -18, Max: 51.25
Current: 35.12
-34.75
51.25
ROC (Joel Greenblatt) % 1323.99
ROC (Joel Greenblatt) ranked higher than
98.94% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NKTR: 1323.99
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -182.91, Med: -108.42, Max: 1323.99
Current: 1323.99
-182.91
1323.99
3-Year Total Revenue Growth Rate 72.90
3-Year Revenue Growth Rate ranked higher than
60.98% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NKTR: 56.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -31.6, Med: 10.3, Max: 62.2
Current: 56.1
-31.6
62.2

» NKTR's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NKTR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:002007 NAS:ASND BOM:532523 NAS:EXEL XAMS:GLPG NAS:ARRY SZSE:300347 NAS:AMRN NAS:ALKS TSE:4587 XBRU:ARGX HKSE:01530 HKSE:01548 NAS:UTHR SZSE:000990 SZSE:002252 XKRX:128940 NAS:NBIX LSE:BTG NAS:FGEN
Traded in other countries ITH.Germany 0UNL.UK
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics Inc is a biopharmaceutical company that seeks to enable the development of new molecules to treat a number of therapeutic areas including oncology, pain, anti-infectives, and immunology. The company's research and development activities involve small-molecule drugs, peptides, and protein biologic drug candidates. The company decides on a candidate-by-candidate basis how far to advance clinical development and whether to commercialize products on its own, seek a partner, or pursue a combination of these approaches. Nektar's partnershipaims to fund continued clinical development, manage the regulatory filing process, and market and sell drugs in various geographies.

Ratios

Current vs industry vs history
PE Ratio (TTM) 9.07
PE Ratio ranked higher than
81.05% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
NKTR: 9.07
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 8.51, Med: 12.22, Max: 432.33
Current: 9.07
8.51
432.33
PE Ratio without NRI 9.07
PE without NRI ranked higher than
81.48% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
NKTR: 9.07
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 8.51, Med: 12.22, Max: 432.33
Current: 9.07
8.51
432.33
Price-to-Owner-Earnings 9.05
Price-to-Owner-Earnings ranked higher than
84.14% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
NKTR: 9.05
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 8.65, Med: 49.62, Max: 141.1
Current: 9.05
8.65
141.1
PB Ratio 3.40
PB Ratio ranked lower than
60.91% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NKTR: 3.4
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.97, Med: 10.76, Max: 1041.36
Current: 3.4
1.97
1041.36
PS Ratio 4.90
PS Ratio ranked higher than
60.47% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NKTR: 4.9
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.76, Med: 9.56, Max: 54.12
Current: 4.9
1.76
54.12
Price-to-Free-Cash-Flow 8.79
Price-to-Free-Cash-Flow ranked higher than
82.89% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
NKTR: 8.79
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.06, Med: 13.74, Max: 65.18
Current: 8.79
8.06
65.18
Price-to-Operating-Cash-Flow 8.54
Price-to-Operating-Cash-Flow ranked higher than
82.38% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
NKTR: 8.54
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.41, Med: 13.17, Max: 30.57
Current: 8.54
4.41
30.57
EV-to-EBIT 6.29
EV-to-EBIT ranked higher than
75.86% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NKTR: 6.29
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -263.8, Med: -12.35, Max: 235.4
Current: 6.29
-263.8
235.4
EV-to-EBITDA 6.19
EV-to-EBITDA ranked higher than
72.24% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NKTR: 6.19
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -1854.2, Med: -10.45, Max: 243.9
Current: 6.19
-1854.2
243.9
EV-to-Revenue 3.73
EV-to-Revenue ranked higher than
68.48% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NKTR: 3.73
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 8.8, Max: 54.1
Current: 3.73
1.5
54.1
Current Ratio 14.94
Current Ratio ranked higher than
90.69% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NKTR: 14.94
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1, Med: 5.94, Max: 19.67
Current: 14.94
1
19.67
Quick Ratio 14.83
Quick Ratio ranked higher than
90.78% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NKTR: 14.83
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.96, Med: 5.87, Max: 19.55
Current: 14.83
0.96
19.55
Days Inventory 185.64
Days Inventory ranked lower than
59.25% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NKTR: 185.64
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 93.11, Med: 142.98, Max: 185.64
Current: 185.64
93.11
185.64
Days Sales Outstanding 13.23
Days Sales Outstanding ranked higher than
89.82% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NKTR: 13.23
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 5.46, Med: 24.79, Max: 57.61
Current: 13.23
5.46
57.61
Days Payable 173.20
Days Payable ranked higher than
70.15% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NKTR: 173.2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 25.29, Med: 43.25, Max: 173.2
Current: 173.2
25.29
173.2

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -8.60
3-Year Share Buyback Rate ranked higher than
70.83% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NKTR: -8.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -21.5, Med: -8, Max: -0.7
Current: -8.6
-21.5
-0.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.56
Price-to-Tangible-Book ranked lower than
53.69% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NKTR: 3.56
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.54, Med: 6.03, Max: 1833.33
Current: 3.56
2.54
1833.33
Price-to-Projected-FCF 3.54
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
62.18% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
NKTR: 3.54
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.4, Med: 3.8, Max: 5.15
Current: 3.54
3.4
5.15
Price-to-Median-PS-Value 0.51
Price-to-Median-PS-Value ranked higher than
59.00% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NKTR: 0.51
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 1.14, Max: 5.55
Current: 0.51
0.2
5.55
Price-to-Graham-Number 1.20
Price-to-Graham-Number ranked higher than
64.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
NKTR: 1.2
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.19, Med: 1.45, Max: 73.33
Current: 1.2
1.19
73.33
Earnings Yield (Joel Greenblatt) % 15.89
Earnings Yield (Greenblatt) ranked higher than
94.17% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NKTR: 15.89
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -27.7, Med: -5.2, Max: 16.8
Current: 15.89
-27.7
16.8

More Statistics

Revenue (TTM) (Mil) $ 1,183.53
EPS (TTM) $ 3.52
Beta 3.42
Volatility % 73
52-Week Range $ 29.22 - 92.17
Shares Outstanding (Mil) 174.31

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 8
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y